MCID: RST001
MIFTS: 52

Restless Legs Syndrome

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Restless Legs Syndrome

MalaCards integrated aliases for Restless Legs Syndrome:

Name: Restless Legs Syndrome 12 76 53 25 54 37 55 44 15 63 73
Restless Leg Syndrome 53 25
Willis-Ekbom Disease 12 25
Wed 12 25
Wittmaack-Ekbom Syndrome 12
Willis Ekbom Disease 53
Ekbom's Syndrome 25
Ekbom Syndrome 25
Restless Legs 43
Rls 25

Classifications:



External Ids:

Disease Ontology 12 DOID:0050425
ICD10 33 G25.81
ICD9CM 35 333.94
MeSH 44 D012148
NCIt 50 C84501
SNOMED-CT 68 32914008 393579008
KEGG 37 H01597
UMLS 73 C0035258

Summaries for Restless Legs Syndrome

NIH Rare Diseases : 53 Restless legs syndrome (RLS) is a neurological condition that causes an irresistible urge to move the legs. The movement is triggered by strange or uncomfortable feelings, which occur mostly while the affected person is sitting or lying down and are worse at night. Movement (i.e. kicking, stretching, rubbing, or pacing) makes the discomfort go away, at least temporarily. Many people with restless legs syndrome also have uncontrollable, repetitive leg movements that occur while they are sleeping or while relaxed or drowsy. Researchers have described early-onset and late-onset forms of restless legs syndrome. The early-onset form begins before age 45 and progresses slowly. The late-onset form begins after age 45, and its signs and symptoms tend to worsen more rapidly. RLS likely results from a combination of genetic and environmental factors, many of which are unknown. The syndrome may also be classified in several types (RLS1, RLS2, RLS3, RLS4, RLS5, RLS6, RLS7) according to the location in specific chromosomes of some of the genes that are associated with an increased risk (susceptibility) to have the syndrome.  Treatment is based on the signs and symptoms present in each person.

MalaCards based summary : Restless Legs Syndrome, also known as restless leg syndrome, is related to restless legs syndrome 6 and restless legs syndrome 7, and has symptoms including back pain, headache and pain. An important gene associated with Restless Legs Syndrome is RLS1 (Restless Legs Syndrome, Susceptibility To), and among its related pathways/superpathways is Ferroptosis. The drugs Gabapentin and gamma-Aminobutyric acid have been mentioned in the context of this disorder. Affiliated tissues include heart, lung and kidney.

MedlinePlus : 43 Restless legs syndrome (RLS) causes a powerful urge to move your legs. Your legs become uncomfortable when you are lying down or sitting. Some people describe it as a creeping, crawling, tingling, or burning sensation. Moving makes your legs feel better, but not for long. RLS can make it hard to fall asleep and stay asleep. In most cases, there is no known cause for RLS. In other cases, RLS is caused by a disease or condition, such as anemia or pregnancy. Some medicines can also cause temporary RLS. Caffeine, tobacco, and alcohol may make symptoms worse. Lifestyle changes, such as regular sleep habits, relaxation techniques, and moderate exercise during the day can help. If those don't work, medicines may reduce the symptoms of RLS. Most people with RLS also have a condition called periodic limb movement disorder (PLMD). PLMD is a condition in which a person's legs twitch or jerk uncontrollably, usually during sleep. PLMD and RLS can also affect the arms. NIH: National Heart, Lung, and Blood Institute

NINDS : 54 Restless legs syndrome (RLS) is characterized by unpleasant sensations in the legs and an irresistible urge to move them. Individuals affected with the disorder often describe the sensations as throbbing, pulling, or creeping. The sensations range in severity from uncomfortable to irritating to painful. Symptoms commonly occur in late afternoon or evening and are most severe at night, when the person is resting. Moving the legs or walking typically relieves the discomfort but the symptoms often recur. RLS is both a sleep and a neurological sensory disorder.

Genetics Home Reference : 25 Restless legs syndrome is a neurological condition that causes an irresistible urge to move the legs. The movement is triggered by strange or uncomfortable feelings, often described as crawling, pulling, or itching, deep within both legs. The feelings usually occur while the affected person is sitting or lying down and are worse at night. Movement, such as kicking, stretching, rubbing, or pacing, make the discomfort go away, at least temporarily. The unpleasant feelings and the resulting need to move the legs often make it difficult for an affected person to fall asleep or stay asleep.

Disease Ontology : 12 A central nervous system disease characterized by throbbing, pulling creeping or other unpleasant sensations in the legs and the irresistible urge to move them.

PubMed Health : 63 About restless legs syndrome: Restless legs syndrome (RLS) is a disorder that causes a strong urge to move your legs. This urge to move often occurs with strange and unpleasant feelings in your legs. Moving your legs relieves the urge and the unpleasant feelings.People who have RLS describe the unpleasant feelings as creeping, crawling, pulling, itching, tingling, burning, aching, or electric shocks. Sometimes, these feelings also occur in the arms.The urge to move and unpleasant feelings happen when you're resting and inactive. Thus, they tend to be worse in the evening and at night.

Wikipedia : 76 Restless legs syndrome (RLS) is a disorder that causes a strong urge to move one\'s legs. There is often... more...

Related Diseases for Restless Legs Syndrome

Diseases related to Restless Legs Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 143)
# Related Disease Score Top Affiliating Genes
1 restless legs syndrome 6 35.0 BTBD9 RLS6
2 restless legs syndrome 7 34.7 MEIS1 RLS7
3 narcolepsy 30.2 ATXN3 DRD2 HCRT
4 friedreich ataxia 1 29.9 ATXN3 FTMT TFRC
5 restless legs syndrome 2 12.6
6 restless legs syndrome 1 12.6
7 restless legs syndrome 3 12.4
8 restless legs syndrome 4 12.4
9 restless legs syndrome 5 12.4
10 restless legs syndrome 8 12.4
11 machado-joseph disease 11.4
12 sleep disorder 11.3
13 fibromyalgia 11.3
14 persistent genital arousal disorder 10.9
15 movement disease 10.6
16 periodic limb movement disorder 10.6
17 depression 10.4
18 neuropathy 10.3
19 multiple sclerosis 10.3
20 iron metabolism disease 10.2
21 aging 10.2
22 kidney disease 10.2
23 attention deficit-hyperactivity disorder 10.2
24 schizophrenia 10.2
25 irritable bowel syndrome 10.2
26 chronic kidney failure 10.1
27 headache 10.1
28 parkinson disease, late-onset 10.1
29 charcot-marie-tooth disease 10.1
30 diabetic neuropathy 10.1
31 sleep apnea 10.1
32 migraine with aura 10.1
33 tooth disease 10.1
34 impulse control disorder 10.1
35 essential tremor 10.1
36 tremor 10.1
37 apnea, obstructive sleep 10.0
38 paine syndrome 10.0
39 diabetes mellitus 10.0
40 spinal cord injury 10.0
41 pathological gambling 10.0
42 polyneuropathy 10.0
43 impotence 10.0
44 bruxism 10.0
45 cerebrovascular disease 10.0
46 myotonic dystrophy 10.0
47 myotonia atrophica 10.0
48 amyotrophic lateral sclerosis 1 9.9
49 arteries, anomalies of 9.9
50 rheumatoid arthritis 9.9

Graphical network of the top 20 diseases related to Restless Legs Syndrome:



Diseases related to Restless Legs Syndrome

Symptoms & Phenotypes for Restless Legs Syndrome

UMLS symptoms related to Restless Legs Syndrome:


back pain, headache, pain, sciatica, seizures, sleep disturbances, snoring, syncope, tremor, chronic pain, vertigo/dizziness, excessive daytime somnolence, sleeplessness

Drugs & Therapeutics for Restless Legs Syndrome

PubMedHealth treatment related to Restless Legs Syndrome: 63

Restless legs syndrome (RLS) has no cure. If a condition or medicine triggers RLS, it may go away or get better if the trigger is relieved or stopped.RLS can be treated. The goals of treatment are to:Prevent or relieve symptomsIncrease the amount of sleep you're getting and improve the quality of your sleepTreat or correct any underlying condition that may trigger or worsen RLSMild cases of RLS often are treated with lifestyle changes and sometimes with periodic use of medicines. More severe RLS usually is treated with daily medicines.

Drugs for Restless Legs Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 262)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 60142-96-3 3446
2
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 56-12-2 119
3
Acetylcholine Approved Phase 4,Phase 2,Phase 1 51-84-3 187
4
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
5
Clopidogrel Approved Phase 4,Phase 3,Phase 2 120202-66-6, 113665-84-2 60606
6
Methylprednisolone Approved, Vet_approved Phase 4,Not Applicable 83-43-2 6741
7
Prednisolone Approved, Vet_approved Phase 4,Not Applicable 50-24-8 5755
8
Ticlopidine Approved Phase 4,Phase 3 55142-85-3 5472
9
Ropinirole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 91374-20-8, 91374-21-9 5095 497540
10
Pramipexole Approved, Investigational Phase 4,Phase 3,Phase 2 104632-26-0 59868 119570
11
Iron Approved Phase 4,Phase 3,Phase 2,Not Applicable 7439-89-6 23925
12
Benzocaine Approved, Investigational Phase 4,Phase 3 1994-09-7, 94-09-7 2337
13
Topiramate Approved Phase 4 97240-79-4 5284627
14
Acetaminophen Approved Phase 4 103-90-2 1983
15
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
16
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
17
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
18
Fluticasone Approved, Experimental, Investigational Phase 4 90566-53-3 62924
19
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2 148553-50-8 5486971
20
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2 52485-79-7 40400 644073
21
Aspirin Approved, Vet_approved Phase 4,Phase 2 50-78-2 2244
22
Amitriptyline Approved Phase 4 50-48-6 2160
23
Donepezil Approved Phase 4 120014-06-4 3152
24
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
25
Memantine Approved, Investigational Phase 4 19982-08-2 4054
26
Propranolol Approved, Investigational Phase 4 525-66-6 4946
27
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
28
Rizatriptan Approved Phase 4 145202-66-0, 144034-80-0 5078
29
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
30
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
31
Zolmitriptan Approved, Investigational Phase 4 139264-17-8 441240 60857
32
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3 1406-16-2
33
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 2,Phase 3 67-97-0 6221 5280795
34 tannic acid Approved, Nutraceutical Phase 4,Phase 3
35 Etiracetam Investigational Phase 4,Phase 2 33996-58-6
36 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Anti-Anxiety Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Antimanic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 calcium channel blockers Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Excitatory Amino Acids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 GABA Agents Phase 4,Phase 3,Phase 1,Not Applicable
47 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 235)
# Name Status NCT ID Phase Drugs
1 Effects of Gabapentin Enacarbil on Arousals, Heart Rate, Blood Pressure and PLMs in Restless Legs Syndrome Unknown status NCT02424695 Phase 4 Gabapentin Enacarbil (GEn);Placebo
2 Effects of Botulinum Toxin Type A(Meditoxin®) on Sleep Bruxism Unknown status NCT01336439 Phase 4 Botulinum toxin type A (Meditoxin®)
3 Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome Post Marketing Commitment Study Completed NCT01668667 Phase 4 GSK1838262 600 mg;GSK1838262 450 mg;GSK1838262 300 mg;GSK1838262 Placebo match
4 12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome Completed NCT00373542 Phase 4 ropinirole CR-RLS
5 Post-marketing Study of Gabapentin Enacarbil to Evaluate the Effect in Restless Leg Syndrome (RLS) Patients With Moderate Renal Impairment Completed NCT01981941 Phase 4 Gabapentin enacarbil
6 Autonomic Function and Cardiovascular Risk in Restless Legs Syndrome Completed NCT02025608 Phase 4 Pramipexole;Placebo
7 Long-term Study Of Ropinirole In Restless Legs Syndrome Completed NCT00329602 Phase 4 Placebo;Ropinirole
8 Restless Legs Syndrome With Iron Deficiency or Anaemia in the 3rd Trimester of Pregnancy Completed NCT01245777 Phase 4 ferric carboxymaltose
9 Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS) Completed NCT00472199 Phase 4 Pramipexole;Placebo
10 Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome Completed NCT01455012 Phase 4 Rotigotine;Placebo
11 Effect of Rotigotine Patch Treatment on Cardiovascular Markers in Idiopathic Restless Legs Syndrome Completed NCT01823770 Phase 4 Rotigotine;Placebo patchs
12 Efficacy and Safety Study of Topiramate to Treat Restless Legs Syndrome Completed NCT00200941 Phase 4 Topiramate
13 Switching From Oral Dopamine Agonists to Rotigotine Completed NCT01976871 Phase 4 Rotigotine
14 SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole Completed NCT00344994 Phase 4 pramipexole
15 A Phase IV Trial With Pramipexole to Investigate the Effects on RLS Symptoms and Sleep Disturbance in Patients With RLS Completed NCT00349531 Phase 4 Pramipexole
16 A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS Completed NCT00375284 Phase 4 Pramipexole
17 Phase IV Trial With Pramipexole to Evaluate Safety and Efficacy in Patients With RLS Associated With Mood Disturbances Completed NCT00356096 Phase 4 pramipexole
18 Treating Sexual Dysfunction From Selective Serotonin Reuptake Inhibitor (SSRI) Medication: a Study Comparing Requip CR to Placebo Completed NCT00334048 Phase 4 Ropinirole (Requip)
19 Early Diuresis Following Colorectal Surgery Completed NCT02351934 Phase 4 Furosemide;Celecoxib;Gabapentin
20 Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease Completed NCT01124422 Phase 4 fluticasone propionate/salmeterol inhalation powder DISKUS 250/50;tiotropium bromide inhalation powder HandiHaler
21 Cholecalciferol Supplementation in Restless Leg Syndrome in Patients With Chronic Kidney Disease Recruiting NCT03063190 Phase 4 Vitamin D;Placebo Oral Tablet
22 An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS Recruiting NCT02560766 Phase 4 HORIZANT 300 mg;HORIZANT 600 mg;Placebo
23 Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease Recruiting NCT03082755 Phase 4 Gabapentin Enacarbil;Placebo Oral Tablet
24 A Study of Oral Dosing of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients Active, not recruiting NCT03053427 Phase 4 Gabapentin enacarbil;Placebo
25 An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS Enrolling by invitation NCT02633683 Phase 4 HORIZANT 600 mg
26 Quality Improvement and Practice Based Research in Neurology Using the EMR Enrolling by invitation NCT02670161 Phase 4 Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
27 Migraine Prophylaxis With Clopidogrel Trial Not yet recruiting NCT02938182 Phase 4 clopidogrel
28 Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome Terminated NCT02117076 Phase 4 Gabapentin immediate release;Gabapentin enacarbil extended release
29 Butrans for Treatment of Restless Legs Syndrome Withdrawn NCT02138357 Phase 4 buprenorphine transdermal delivery system (BTDS);Placebo for BTDS patch
30 Pregabalin (Lyrica) for the Treatment of Restless Legs Syndrome Withdrawn NCT00584246 Phase 4 Pregabalin (Lyrica);Placebo
31 RCT Comparing Standard Cannula Delivered FS, UGFS and ClariVein® in the Management of SVI Withdrawn NCT02010437 Phase 4 Sodium Tetradecyl Sulphate (STS)
32 Vitamin D in the Treatment of Primary Restless Legs Syndrome Unknown status NCT02256215 Phase 2, Phase 3 Vitamin D
33 Effects of Cognitive-Behavioral Therapy on Sleep Disturbance in Peritoneal Dialysis Patients Unknown status NCT00155441 Phase 3
34 A Multicenter Trial to Assess the MIcrovascular Integrity and Left Ventricular Function Recovery After Clopidogrel or TicagrelOr Administration, in Patients With STEMI Treated With Thrombolysis - The 'MIRTOS' Study Unknown status NCT02429271 Phase 3 Ticagrelor;Clopidogrel
35 Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients Completed NCT00806026 Phase 3 placebo and pregabalin;pramipexol;pramipexol;Pregabalin;pramipexol;pramipexol
36 Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS) Completed NCT01569464 Phase 3 Rotigotine
37 Bupropion and Restless Legs Syndrome Completed NCT00621517 Phase 2, Phase 3 Bupropion;Placebo
38 Long-term Efficacy and Safety of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients Completed NCT02658188 Phase 3 ASP8825
39 Study of SPM 962 in Patients With Restless Legs Syndrome (RLS) Completed NCT01084551 Phase 3 SPM 962;SPM 962;Placebo of SPM 962
40 Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance Completed NCT00991276 Phase 3 pregabalin;placebo;pramipexole
41 RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole Completed NCT00314860 Phase 3 ropinirole Extended Release (XR)
42 Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome) Completed NCT00256854 Phase 3 ropinirole controlled-release for RLS
43 Pramipexole in Out-patients With Idiopathic Restless Legs Syndrome (IRLS) Completed NCT00654498 Phase 3 Pramipexole;Placebo
44 Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome Completed NCT00197080 Phase 3 Ropinirole Extended Release (XR)
45 XP13512 (Gabapentin Enacarbil) Extension Study in Patients With Restless Legs Syndrome. Completed NCT00333359 Phase 3 XP13512 (GEn)
46 Transdermal Lisuride: a Trial for the Treatment of Patients With Restless Legs Syndrome (RLS) Completed NCT00367822 Phase 3 Lisuride;Ropinirole;Placebo
47 An Extension Trial to Investigate Long-Term Treatment With Transdermal Rotigotine in Idiopathic Restless Legs Syndrome Completed NCT00263068 Phase 3 Rotigotine
48 A Clinical Research Study Evaluating Ropinirole Treatment For Restless Legs Syndrome (RLS) Completed NCT00225862 Phase 3 ropinirole
49 Phase 3 Open-label Extension Trial With Rotigotine in Idiopathic Restless Legs Syndrome Subjects Completed NCT00498108 Phase 3 Rotigotine
50 Long-Term Safety Of Ropinirole XR In Patients With Restless Legs Syndrome Completed NCT00355641 Phase 3 Ropinirole Extended Release (XR)

Search NIH Clinical Center for Restless Legs Syndrome

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: restless legs syndrome

Genetic Tests for Restless Legs Syndrome

Anatomical Context for Restless Legs Syndrome

MalaCards organs/tissues related to Restless Legs Syndrome:

41
Heart, Lung, Kidney, Brain, Testes, Spinal Cord, Bone

Publications for Restless Legs Syndrome

Articles related to Restless Legs Syndrome:

(show top 50) (show all 831)
# Title Authors Year
1
Effect of Near-Infrared Light Therapy Based on Acupoints on the Severity of Restless Legs Syndrome in Patients Undergoing Hemodialysis: A Single-Blind Randomized Controlled Trial. ( 29776916 )
2018
2
Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. ( 29425576 )
2018
3
Restless Legs Syndrome Negatively Impacts Worker Health and Safety. ( 29897020 )
2018
4
Association between serum hepcidin level and restless legs syndrome. ( 29418021 )
2018
5
Altered Brain Functional Connectome in Migraine with and without Restless Legs Syndrome: A Resting-State Functional MRI Study. ( 29441041 )
2018
6
Chronic back pain cured by low-dose levodopa: is it a variant of restless legs syndrome? ( 29440925 )
2018
7
Chronic pulmonary disease is associated with pain spreading and restless legs syndrome in middle-aged women-a population-based study. ( 29869108 )
2018
8
Pharmacologic and Nonpharmacologic Treatment of Restless Legs Syndrome. ( 29759272 )
2018
9
Diurnal variation of default mode network in patients with restless legs syndrome. ( 29425573 )
2018
10
The prevalence of restless legs syndrome and its relationship with demographic characteristics and medical disorders in postmenopausal Iranian women. ( 29419360 )
2018
11
Lack of Association Between Shape and Volume of Subcortical Brain Structures and Restless Legs Syndrome. ( 29867753 )
2018
12
Restless Legs Syndrome/Willis-Ekbom Disease Is Prevalent in Working Nurses, but Seems Not to Be Associated with Shift Work Schedules. ( 29434568 )
2018
13
Impaired short-term plasticity in restless legs syndrome: a pilot rTMS study. ( 29773202 )
2018
14
Restless Legs Syndrome and Periodic Limb Movements During Sleep in the Multi-Ethnic Study of Atherosclerosis (MESA). ( 29860522 )
2018
15
Additional Safety Considerations Before Prescribing Opioids to Manage Restless Legs Syndrome. ( 29976377 )
2018
16
Predictors of clinical response in a double-blind placebo controlled crossover trial of gabapentin enacarbil for restless legs syndrome. ( 29807228 )
2018
17
Leg Movement Activity during Sleep in School-Age Children and Adolescents: A Detailed Study in Normal Controls and Subjects with Restless Legs Syndrome and Narcolepsy Type 1. ( 29365206 )
2018
18
Istradefylline for Restless Legs Syndrome Associated with Parkinson's Disease. ( 29423337 )
2018
19
Morning cortisol and fasting glucose are elevated in women with chronic widespread pain independent of comorbid restless legs syndrome. ( 29794301 )
2018
20
Response to comments on: "Complementary and alternative therapies for restless legs syndrome: An evidence-based systematic review" - by Mohammad Alwardat. ( 29886027 )
2018
21
Polysomnographic findings in restless legs syndrome (RLS) patients with severe augmentation. ( 29860190 )
2018
22
Haplotype Association of the<i>MAP2K5</i>Gene with Antipsychotics-Induced Symptoms of Restless Legs Syndrome among Patients with Schizophrenia. ( 29422930 )
2018
23
Higher Prevalence of Hypertension among Individuals with Restless Legs Syndrome: A Meta-Analysis. ( 29898579 )
2018
24
The relationship with restless legs syndrome, fibromyalgia, and depressive symptoms in migraine patients. ( 29777478 )
2018
25
Restless Legs Syndrome in Iranian People With Type 2 Diabetes Mellitus: The Role in Quality of Life and Quality of Sleep. ( 29351820 )
2018
26
Rate of augmentation and risk factors with long-term follow-up in Japanese patients with restless legs syndrome. ( 29845566 )
2018
27
Diabetic Painful Neuropathy and Restless Legs Syndrome in Diabetes. ( 29427229 )
2018
28
Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)<sup>As</sup>. ( 29756335 )
2018
29
The Appropriate Use of Opioids in the Treatment of Refractory Restless Legs Syndrome. ( 29304922 )
2018
30
Patients with primary restless legs syndrome have higher prevalence of autonomic dysfunction and irritable bowel syndrome. ( 29372261 )
2018
31
In Reply-Additional Safety Considerations Before Prescribing Opioids to Manage Restless Legs Syndrome. ( 29976378 )
2018
32
Restless Legs Syndrome: AnA Unresolved Uremic Disorder after Renal Transplantation. ( 29393274 )
2018
33
TOX3 Variants Are Involved in Restless Legs Syndrome and Parkinson's Disease with Opposite Effects. ( 29404899 )
2018
34
Psoriasis Is Associated With a Higher Prevalence of Obstructive Sleep Apnea and Restless Legs Syndrome: A Possible Indication of Autonomic Activation in Psoriasis. ( 29852915 )
2018
35
Effective treatment of restless legs syndrome by safinamide in Parkinson's disease patients. ( 29268951 )
2018
36
Acute-onset Restless legs syndrome in acute neurological conditions-a prospective study on patients with the Guillain-Barre syndrome and acute stroke. ( 29359321 )
2018
37
Comments on: &amp;quot;Complementary and alternative therapies for restless legs syndrome: An evidence-based systematic review&amp;quot;. ( 29887255 )
2018
38
Insomnia and Psychopathological Features Associated With Restless Legs Syndrome in Chinese Adolescents. ( 29325239 )
2018
39
Association of Hemodialysis Inadequacy and Duration with Restless Legs Syndrome: A Cross-sectional Study. ( 29974025 )
2018
40
Restless legs syndrome and cerebrovascular/cardiovascular events: Systematic review and meta-analysis. ( 28948600 )
2017
41
Prevalence of restless legs syndrome during detoxification from alcohol and opioids. ( 28017182 )
2017
42
Obesity: a possible risk factor for restless legs syndrome. ( 28944745 )
2017
43
Thr105Ile (rs11558538) polymorphism in the histamine-1-methyl-transferase (HNMT) gene and risk for restless legs syndrome. ( 27837280 )
2017
44
Uremic Restless Legs Syndrome Pleads &amp;quot;Not Guilty&amp;quot;. ( 28869930 )
2017
45
Targeted disruption of supraspinal motor circuitry reveals a distributed network underlying Restless Legs Syndrome (RLS)-like movements in the rat. ( 28852150 )
2017
46
Association of BTBD9 and MAP2K5/SKOR1 With Restless Legs Syndrome in Chinese Population. ( 28329290 )
2017
47
Pivotal Role of Adenosine Neurotransmission in Restless Legs Syndrome. ( 29358902 )
2017
48
Pharmacological Management of Restless Legs Syndrome and Periodic Limb Movement Disorder in Children. ( 28831753 )
2017
49
Plantar reflex excitability is increased in the evening in restless legs syndrome patients. ( 28917979 )
2017
50
Abnormal Sleep Delta Rhythm and Interregional Phase Synchrony in Patients with Restless Legs Syndrome and Their Reversal by Dopamine Agonist Treatment. ( 28831786 )
2017

Variations for Restless Legs Syndrome

Expression for Restless Legs Syndrome

Search GEO for disease gene expression data for Restless Legs Syndrome.

Pathways for Restless Legs Syndrome

Pathways related to Restless Legs Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.23 FTMT TFRC

GO Terms for Restless Legs Syndrome

Biological processes related to Restless Legs Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 modulation of chemical synaptic transmission GO:0050804 9.16 BTBD9 DRD2
2 long-term memory GO:0007616 8.96 BTBD9 DRD2
3 temperature homeostasis GO:0001659 8.62 DRD2 HCRT

Sources for Restless Legs Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....